{
    "ticker": "XOMA",
    "name": "XOMA Corporation",
    "description": "XOMA Corporation is a biotechnology company focused on developing and commercializing innovative therapeutics for unmet medical needs. Founded in 1981 and based in Berkeley, California, XOMA has a rich history of pioneering work in the field of monoclonal antibodies and other biologics. The company's primary focus is on leveraging its extensive expertise in antibody development to create diverse therapeutic solutions for various diseases, including autoimmune disorders, cancer, and infectious diseases. XOMA's proprietary technologies include the XOMA 3AB platform, which is designed to generate novel antibodies that target specific disease-causing mechanisms. In addition to its internal development programs, XOMA collaborates with other biotechnology and pharmaceutical companies to enhance the therapeutic potential of their candidates. The company is committed to advancing science and improving patient outcomes through its innovative product pipeline and strategic partnerships. With a deep understanding of the complexities of biologic drug development, XOMA continues to contribute to the biopharmaceutical landscape, aiming to address significant health challenges and deliver transformative therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Berkeley, California, USA",
    "founded": "1981",
    "website": "https://www.xoma.com",
    "ceo": "Jim Neal",
    "social_media": {
        "twitter": "https://twitter.com/XOMA_Corp",
        "linkedin": "https://www.linkedin.com/company/xoma-corporation/"
    },
    "investor_relations": "https://investors.xoma.com",
    "key_executives": [
        {
            "name": "Jim Neal",
            "position": "CEO"
        },
        {
            "name": "Michele Garvey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "XOMA 3AB",
                "XOMA 521"
            ]
        }
    ],
    "seo": {
        "meta_title": "XOMA Corporation | Innovating Biotherapeutics for Unmet Needs",
        "meta_description": "Explore XOMA Corporation, a leader in biotechnology dedicated to developing innovative therapeutics for various medical conditions. Learn about XOMA's pioneering products and commitment to improving patient outcomes.",
        "keywords": [
            "XOMA",
            "Biotechnology",
            "Pharmaceuticals",
            "Therapeutics",
            "Monoclonal Antibodies",
            "XOMA 3AB"
        ]
    },
    "faq": [
        {
            "question": "What is XOMA known for?",
            "answer": "XOMA is known for developing innovative therapeutics, particularly monoclonal antibodies for various diseases."
        },
        {
            "question": "Who is the CEO of XOMA?",
            "answer": "Jim Neal is the CEO of XOMA Corporation."
        },
        {
            "question": "Where is XOMA headquartered?",
            "answer": "XOMA is headquartered in Berkeley, California, USA."
        },
        {
            "question": "What are XOMA's main products?",
            "answer": "XOMA's main products include XOMA 3AB and XOMA 521."
        },
        {
            "question": "When was XOMA founded?",
            "answer": "XOMA was founded in 1981."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX",
        "BMRN"
    ],
    "related_stocks": [
        "GILD",
        "ABBV",
        "MRNA",
        "NVAX"
    ]
}